
Release date: 2026-01-20 17:03:03 Article From: Lucius Laos Recommended: 91
Ponatinib is indicated for the treatment of patients with chronic-phase chronic myeloid leukemia (CML) who have previously received at least two other therapies with inadequate efficacy.
This medicine can also be used to treat patients with accelerated-phase or blast-phase chronic myeloid leukemia (CML) who are unable to receive any other medications. Ponatinib is equally indicated for patients with chronic-phase, accelerated-phase or blast-phase CML who carry a specific abnormal genetic subtype (T315I-positive). Leukemia is a type of blood cancer characterized by the production of abnormal white blood cells in the body.
Ponatinib can also be used in combination with chemotherapy for the treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). For patients who cannot receive other medications or carry the specific abnormal genetic subtype (T315I-positive), this medicine may be administered alone.
Before taking this medicine, you should inform your healthcare team of the following conditions:
Whether you have bleeding disorders, thrombosis, diabetes, recent or planned surgery, heart attack, heart disease, heart failure, hypertension, hypercholesterolemia, arrhythmia, liver disease, pancreatic disease, or stroke;
Whether you have had abnormal reactions or allergies to this medicine (ponatinib), other drugs, foods, dyes, or preservatives;
Whether you are pregnant, planning to become pregnant, or breastfeeding.
How to take: Swallow the tablet whole with warm water. Do not cut, crush, or chew it. Take the medicine at a fixed time every day as directed on the prescription label, either with food or on an empty stomach. If gastric discomfort occurs, it is recommended to take it with meals. Continue taking the medicine unless otherwise instructed by your healthcare team. Note: Do not consume grapefruit juice during the treatment period.
Your pharmacist will provide you with a dedicated medication guide each time you pick up your prescription; please be sure to read it carefully. For the use of this medicine in children, consult your healthcare team in detail, as special precautions may be required.
In case of overdose, contact a poison control center or emergency room immediately.
Important Warning: This medicine is for your personal use only. Do not share it with others.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643